SCHEMBL24630902

SCHEMBL24630902

COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc3c(n2)NCCO3)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 14/20 0.47
ADRB3 P13945 6/20 0.42
ADRB1 P08588 7/20 0.41
DRD2 P14416 2/20 0.41
PGR P06401 1/20 0.41
SLC6A4 P31645 1/20 0.41
ADRA1A P35348 1/20 0.41
PTGS2 P35354 1/20 0.41
SLC6A3 Q01959 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
DRD3 P35462 1/20 0.41
ITGB3 P05106 1/20 0.38
ITGB1 P05556 1/20 0.38
ITGAV P06756 1/20 0.38
ITGA5 P08648 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24630981 0.84 ADRB2 (0.51) ADRB2ADRB3ADRB1DRD2PGR
SCHEMBL24630900 0.83 ADRB2 (0.47) ADRB2ADRB3ADRB1
SCHEMBL24630954 0.75 ADRB2 (0.52) ADRB2ADRB3ADRB1DRD2PGR
SCHEMBL24630901 0.74 HIF1A (0.47) ADRB2ADRB3ADRB1CYP3A4CYP2D6
SCHEMBL7153097 0.70 ADRB2 (0.78) ADRB2ADRB3ADRB1DRD2PGR
SCHEMBL7153093 0.70 ADRB2 (0.78) ADRB2ADRB3ADRB1DRD2PGR
SCHEMBL22481208 0.69 ADRB1 (0.54) ADRB2ADRB3ADRB1DRD2PGR
SCHEMBL22480777 0.69 ADRB2 (0.53) ADRB2ADRB3ADRB1DRD2PGR
SCHEMBL22481092 0.69 ADRB1 (0.54) ADRB2ADRB3ADRB1DRD2PGR
SCHEMBL26048506 0.69 ADRB2 (0.50) ADRB2ADRB3ADRB1DRD2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220315534-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. 2022-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315534-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME ADRB2, ADRB1, ADRA2C ADRB2 1/4885ADRB3 4/4885ADRB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.